One of the most widely prescribed antidepressant medications in the U.S. has fallen into short supply, according to a new list from the FDA. Pfizer (NYSE:PFE) said some versions of its name-brand Zoloft, such as 100 milligram tablets in 100-count bottles, were scarce because of higher demand during COVID-19, while generics faced shortages of certain ingredients. Zoloft prescriptions climbed 12% Y/Y to 4.9M in March, the most ever in the U.S., according to data compiled by Bloomberg, but receded to 4.5M in April.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Justo yo ayer entré en AXSM AXS-05 is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer’s disease agitation, major depressive disorder, and other central nervous system (CNS) disorders. AXS-05 consists of a proprietary formulation and dose of dextromethorphan and bupropion and utilizes Axsome’s metabolic inhibition technology. The dextromethorphan component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, a sigma-1 receptor agonist, an inhibitor of the serotonin and norepinephrine transporters, a nicotinic acetylcholine receptor antagonist, and an inhibitor of microglial activation. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. AXS-05 is covered by more than 42 issued U.S. and international patents which provide protection out to 2034. AXS-05 has been granted U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of MDD, as well as Fast Track designations for the treatment of Alzheimer’s disease agitation and treatment resistant depression. AXS-05 is not approved by the FDA.
